Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.0K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

590
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
590
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

310
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
310
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bacteriophage Therapy Against <i>Shigella</i> spp.: A Precision Antimicrobial Strategy.

Antibiotics (Basel, Switzerland)·2026
Same author

Liver and spleen stiffness as assessed by vibration-controlled transient elastography for diagnosing clinically significant portal hypertension in comparison with other elastography-based techniques in adults with chronic liver disease.

The Cochrane database of systematic reviews·2026
Same author

CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.

Acta clinica Croatica·2025
Same author

GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease.

The Cochrane database of systematic reviews·2024
Same author

Correlation of the severity of the clinical presentation of SARS-CoV-2 pneumonia with respiratory function parameters in the post-COVID period.

Journal of infection in developing countries·2024
Same author

The Influence of Hemochromatosis Gene <i>(HFE)</i> Mutations on SARS-CoV-2 Susceptibility and COVID-19 Severity

Balkan medical journal·2023
Same journal

[CHARACTERISTIC FEATURES OF PRESSURE ULCER INFECTION].

Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti·2017
Same journal

[PERSONALIZED APPROACH TO PATIENT WITH CHRONIC WOUND IN FAMILY MEDICINE].

Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti·2017
Same journal

[APPLICATION OF TOPICAL HEMOGLOBIN SPRAY IN INFECTED POSTTRAUMATIC AND POSTOPERATIVE WOUNDS].

Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti·2017
Same journal

[APPLICATION OF NEGATIVE PRESSURE THERAPY].

Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti·2017
Same journal

[PATIENTS WITH PRESSURE ULCERS IN THE UNIFIED EMERGENCY ADMISSION DEPARTMENT – OUR REALITY].

Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti·2017
Same journal

[Proposition of algorhythm for treatment with hyperbaric oxygenation Hyperbaric oxygenation in Rijeka Clinical Hospital Center].

Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti·2017
See all related articles

Related Experiment Video

Updated: Feb 6, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

[Hepatitis C: who should be treated?].

Davor Stimac1, Sandra Milić

  • 1Gastroenteroloski odjel, Klinika za internu medicinu, Klinicki bolnicki centar Rijeka, Rijeka, Hrvatska. davor.stimac@ri.htnet.hr

Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti
|December 31, 2005
PubMed
Summary
This summary is machine-generated.

Hepatitis C treatment aims to eradicate the virus and prevent liver disease. Key factors for treatment decisions include disease stage, comorbidities, and potential risks, guiding therapy recommendations for various patient groups.

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K

Related Experiment Videos

Last Updated: Feb 6, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Context:

  • Hepatitis C (HCV) infection poses a significant global health burden, necessitating effective treatment strategies.
  • Treatment goals include viral eradication and preventing advanced liver disease.
  • Clinical decision-making for HCV therapy requires careful consideration of multiple patient-specific factors.

Purpose:

  • To outline the criteria for initiating hepatitis C treatment.
  • To identify patient populations who benefit from therapy.
  • To define contraindications and specific considerations for HCV treatment.

Summary:

  • Treatment is recommended for patients with elevated ALT, significant fibrosis (F2 METAVIR score), prior non-response to interferon, compensated cirrhosis, and acute infection.
  • HCV treatment is feasible in patients with HBV/HIV co-infection, severe extrahepatic manifestations, and liver transplants.
  • Patients with a history of substance abuse require 12-month abstinence; therapy is contraindicated in fulminant hepatitis, normal ALT without fibrosis, kidney transplant recipients, and pregnant women.

Impact:

  • Optimizing treatment selection improves patient outcomes and reduces the incidence of end-stage liver disease.
  • This guidance aids clinicians in making informed decisions for hepatitis C management.
  • Effective treatment strategies contribute to the global effort to control and eliminate hepatitis C.